HHS awards contract to make COVID-19 drug ingredients, generics in U.S.

May 19, 2020 - 02:57 PM
stock-prescription-pill-bottle_900x400

The Department of Health and Human Services today announced a $354 million agreement with a private partnership to make more active pharmaceutical ingredients and generic drugs in the United States to treat patients hospitalized with COVID-19 and prevent shortages of essential medicines.

Under the four-year agreement, Phlow Corporation will partner with Civica Rx, the nonprofit generic drug company created by hospital systems and others; AMPAC Fine Chemicals; the Medicines for All Institute at Virginia Commonwealth University’s College of Engineering and others to rapidly make the active pharmaceutical ingredients and medicines using advanced manufacturing processes.

The contract can be extended up to 10 years to maintain the system and supplies.

Related News Articles

Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
OSHA extends comment period on proposal removing remaining COVID-19 emergency temporary standard requirements
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…